Role of action potential configuration and the contribution of C²⁺a and K⁺ currents to isoprenaline-induced changes in canine ventricular cells

Br J Pharmacol. 2012 Oct;167(3):599-611. doi: 10.1111/j.1476-5381.2012.02015.x.

Abstract

Background and purpose: Although isoprenaline (ISO) is known to activate several ion currents in mammalian myocardium, little is known about the role of action potential morphology in the ISO-induced changes in ion currents. Therefore, the effects of ISO on action potential configuration, L-type Ca²⁺ current (I(Ca)), slow delayed rectifier K⁺ current (I(Ks)) and fast delayed rectifier K⁺ current (I(Kr)) were studied and compared in a frequency-dependent manner using canine isolated ventricular myocytes from various transmural locations.

Experimental approach: Action potentials were recorded with conventional sharp microelectrodes; ion currents were measured using conventional and action potential voltage clamp techniques.

Key results: In myocytes displaying a spike-and-dome action potential configuration (epicardial and midmyocardial cells), ISO caused reversible shortening of action potentials accompanied by elevation of the plateau. ISO-induced action potential shortening was absent in endocardial cells and in myocytes pretreated with 4-aminopyridine. Application of the I(Kr) blocker E-4031 failed to modify the ISO effect, while action potentials were lengthened by ISO in the presence of the I(Ks) blocker HMR-1556. Both action potential shortening and elevation of the plateau were prevented by pretreatment with the I(Ca) blocker nisoldipine. Action potential voltage clamp experiments revealed a prominent slowly inactivating I(Ca) followed by a rise in I(Ks) , both currents increased with increasing the cycle length.

Conclusions and implications: The effect of ISO in canine ventricular cells depends critically on action potential configuration, and the ISO-induced activation of I(Ks) - but not I(Kr) - may be responsible for the observed shortening of action potentials.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Action Potentials / drug effects*
  • Adrenergic beta-Agonists / pharmacology
  • Animals
  • Calcium Channels, L-Type / metabolism
  • Chromans / pharmacology
  • Delayed Rectifier Potassium Channels / metabolism*
  • Dogs
  • Female
  • Isoproterenol / pharmacology*
  • Male
  • Myocytes, Cardiac / drug effects*
  • Myocytes, Cardiac / metabolism
  • Nisoldipine / pharmacology
  • Patch-Clamp Techniques
  • Piperidines / pharmacology
  • Pyridines / pharmacology
  • Sulfonamides / pharmacology

Substances

  • Adrenergic beta-Agonists
  • Calcium Channels, L-Type
  • Chromans
  • Delayed Rectifier Potassium Channels
  • HMR 1556
  • Piperidines
  • Pyridines
  • Sulfonamides
  • E 4031
  • Nisoldipine
  • Isoproterenol